Does Pharmacological Treatment Reduce the Incidence of Lower Urinary Tract Symptoms (LUTS) after Transobturator Sling?

Autor:	Tomasz Rechberger, Michał Bogusiewicz, Alicja Zietek, Ewa Rechberger, Beata Kulik-Rechberger, Pawel Miotla, Andrzej Wróbel
Rok vydání:	2019
Předmět:	Adult medicine.medical_specialty Article Subject 030232 urology & nephrology Urology lcsh:Medicine Urinary incontinence General Biochemistry Genetics and Molecular Biology law.invention 03 medical and health sciences 0302 clinical medicine Lower Urinary Tract Symptoms Randomized controlled trial Lower urinary tract symptoms law medicine Humans Nocturia Prospective Studies Prospective cohort study Aged Suburethral Slings 030219 obstetrics & reproductive medicine Solifenacin General Immunology and Microbiology business.industry lcsh:R Solifenacin Succinate General Medicine Middle Aged medicine.disease Thiazoles Ambulatory Acetanilides Female medicine.symptom business Mirabegron Research Article medicine.drug
Zdroj:	BioMed Research International, Vol 2019 (2019) BioMed Research International
ISSN:	2314-6141 2314-6133
DOI:	10.1155/2019/7271289
Popis:	Aim. Lower urinary tract symptoms (LUTS) frequently affect patients immediately after midurethral sling (MUS) placement. The objective of the study was to assess if solifenacin or mirabegron decreases incidence of LUTS in women who underwent transobturator MUS. Methods. A prospective randomized trial was conducted on patients undergoing ambulatory transobturator midurethral sling due to stress urinary incontinence (SUI). All participants were questioned before and after surgery for occurrence of bothersome LUTS. A total of 328 patients who underwent transobturator MUS were randomly assigned to one of three groups: prophylaxis with 10 mg of solifenacin, prophylaxis with 50 mg of mirabegron, or without any additional treatment. LUTS evolution and efficacy of solifenacin and mirabegron were analyzed based on results of assessments made during follow-up visits at 1 and 6 weeks after surgery. Comparison of the prevalence of LUTS was done using chi2 test. Results. Prevalence of urgency and frequency episodes increased notably 1 week after sling placement and then came down to baseline levels. Solifenacin and mirabegron significantly reduced the incidence of urgency after 1 week, but after 6 weeks the beneficial effect was observed only in case of solifenacin. Treatment with mirabegron reduced the percentage of patients suffering from frequency after 6 weeks. Although prevalence of nocturia did not raise after sling placement, both treatments significantly reduced the incidence of this complaint after 6 weeks. Pharmacological treatment did not modulate the course of hesitancy and terminal dribbling. Conclusions. Treatment with solifenacin or mirabegron may significantly reduce the incidence of undesired LUTS after MUS.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d299633447f1f19761450fae47a2849 https://doi.org/10.1155/2019/7271289 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.